NanoViricides has completed an underwritten public offering with gross proceeds of $11.5 million. The company is developing antiviral therapies based on a novel nanomedicines platform.
NanoViricides is working with its regulatory consultants to advance its lead drug candidate NV-HHV-101 into human clinical trials for topical dermal treatment of Shingles rash as the initial indication. The Company has also reported strong effectiveness as well as strong safety in relevant animal models of its drug candidates in development for the treatment of SARS-CoV-2 infection which leads to COVID-19 disease.